Precision Medicines is dedicated to improving the lives of cancer patients through developing novel targeted medicines with companion biomarkers.
Precision Medicines develops cancer medicines with companion biomarkers targeted to the specific drivers of various cancers.
Precision Medicines in-licenses oncology therapies across all phases of development to develop alongside companion biomarkers.
Precision Medicines collaborates with biotech, pharma, academic and clinical centres globally to develop novel cancer therapies and companion biomarkers.
Precision Medicines is led by a management team and advisors that have developed, gained regulatory approval and commercialised major cancer medicines around the world.